目的 探讨奈达铂与顺铂联合放疗治疗中晚期食管癌的近期疗效及不良反应.方法 选取64例经病理学或细胞学确诊的无法手术的初治中晚期食管癌患者,随机分组,32例人奈达铂联合放疗组(治疗组),32例人顺铂联合放疗组(对照组).同时评价疗效及不良反应.结果 治疗组有效率(RR)为69%,对照组为53%,两者比较,差异有统计学意义(P<0.05).主要不良反应为骨髓抑制、放射性食管炎,发生率治疗组与对照组差异无统计学意义(P>0.05),恶心呕吐及肾毒性发生率治疗组低于对照组(P<0.05).结论 奈达铂联合放疗治疗中晚期食管癌取得较高的临床疗效,且不良反应可耐受.%Objective To investigate the efficacy and toxicity of Nedaplatin and Cisplalin combined with radiotherapy forrnpaiienis with advanced esophageal cancer. Methods 64 patients with untreated advanced esophageal cancer were enrolledrnin this study and all of these patients were confirmed with pathology or cytology and all of them were found no chance tornreceive surgery treatment. These patients were randomly divided into two groups, 32 patients in treatment group werernreceived Nedaplatin combined with radiotherapy and 32 patients in control group were received Cisplatin combined withrnradiotherapy. Results The effective rate in treatment group was 69% and that in contra! group was 53%, the difference wasrnstatistically significant (P ＜ 0.05). Bone marrow suppression and radiation-Induced esophagitis were the major adversernreactions, the differences of the Incidences between the two groups were not statistically significant (P ＞ 0.05), but therndifferences of the Incidences of cmesls and renal impairment in the two groups were statistically significant (P ＜ 0.05).rnConclusion Nedaplatin combined with radiotherapy Is effective in treatment of advanced esophageal cancer and the toxicityrncan be well tolerated.
展开▼
